

بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار






بعض الوثائق الأصلية تالفة





بالرسالة صفحات
لم ترد بالأصل





Ain shams University
Faculty of Science
Microbiology Dept.

Serological Studies on Circulating Interferon- γ in Patients Infected with Hepatitis C Virus

A Thesis

**Submitted for the degree of doctor of philosophy
in Microbiology (Virology)**

By

Rashed Ebrahim Rashed Al Najdi

B.Sc (Microbiology, 2005)

M.Sc (Microbiology, 2013)

Microbiology Dept., Faculty of Science Ain shams University

SUPERVISORS

Prof. Dr. Ahmed Barakat Barakat

Professor of Virology

Microbiology Dept., Faculty of Science

Ain shams University

Prof. Dr. Sahar Ahmed Hafez Shoman

Professor of Virology

Microbiology Dept., Faculty of Science

Ain shams University

Prof. Dr. Abdelfattah Mohammed Attallah

Professor of Immunology and Genetics

Director of Biotechnology Research Center,

New Damietta

Microbiology department

Faculty of science

Ain shams university

2020

Approval Sheet

Serological Studies on Circulating Interferon- γ in Patients Infected with Hepatitis C Virus

A Thesis

**Submitted for the degree of doctor of philosophy
in Microbiology (Virology)**

By

Rashed Ebrahim Rashed Al Najdi

B.S (Microbiology, 2005)

M.Sc (Microbiology, 2013)

Microbiology Dept., Faculty of Science Ain shams University

Supervisors

Prof. Dr. Ahmed Barakat Barakat

Professor of Virology

Microbiology Department

Faculty of Science - Ain Shams University

Prof. Dr. Sahar Ahmed Hafez Shoman

Professor of Virology

Microbiology Department

Faculty of Science - Ain Shams University

Prof. Dr. Abdelfattah Mohammed Attallah

Professor of Immunology and Genetics

Director of Biotechnology Research Center, New Damietta

Approved by:

- Prof.Dr. Mahmoud Mohammed Bahgat

- Prof.Dr. Mohammed Mabrouk Mohammed Aboulwafa

- Prof. Dr. Ahmed Barakat Barakat

- Prof. Dr. Sahar Ahmed Hafez Shoman

Examination Date:

Graduate studies:

Faculty approval:

University approval:

Microbiology Department

Faculty of Science

Ain Shams University

2020

Acknowledgments

الحمد لله رب العالمين

*I express my deepest thanks and great appreciation to **Prof. Dr. Ahmed Barakat Barakat**, Professor of Virology, Microbiology Department, Faculty of Science, Ain Shams University, for his kind supervision, guidance, encouragement as well as his continuous help and endless support.*

*My deepest gratitude and appreciation to **Prof. Dr. Sahar Ahmed Hafez Shoman**, Professor of Virology, Microbiology Department, Faculty of Science, Ain Shams University, for her great assistance, helpful supervision and invaluable support throughout all steps of this work.*

*I would like to express my sincere thanks and gratitude to **Prof. Dr. Abdelfattah Mohammed Attallah**, Professor of Immunology and Genetics, Director of Biotechnology Research Center, New Damietta, for his guidance, advice and continuous help.*

My sincere gratitude to my father, mother and all members of my big family for their encouragement and support during all steps of this work and all my life. Finally, grateful thanks to my Wife and my children.

*Special thanks to microbiology department, faculty of science, ain shams university members for their encouragement and help as well as to all my faithful friends whom supported me sychologically and practically, especially **Mr. Mohammed El-Bendary**.*



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا إِنَّكَ
أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم
سورة البقرة آية (٣٢)



Contents

Chapter (I): Introduction	1
Aim of the work	4
Chapter (II): Review of Literature	5
1. Molecular characteristics and Life cycle of HCV	5
2. Distribution of HCV genotypes	13
3. Global epidemiology and natural history of hepatitis C virus infection	14
4. Risk and transmission factors	19
4.1 Transfusion of blood products	19
4.2 Intravenous drug use	19
4.3 Medical procedures and nosocomial exposure	19
4.4 Solid organ transplantation	20
4.5 Occupational exposure	20
4.6 Vertical transmission	20
4.7 Sexual transmission	20
5. Hepatitis C virus-induced hepatocellular carcinoma	21
5.1 Pathogenesis of HCV-induced HCC	22
5.2 Interaction of HCV with cellular pathways	23
5.3 Assessment of risk of HCC in HCV-infected individuals	24
6. HCV in Egypt	25
6.1 History of the infection with HCV	27
6.2 The effects of HCV on the liver	28
6.3 Previous and current treatments	29
6.4 Efficacy of treatment with sofosbuvir and ribavirin	29
6.5 Accessibility of treatment	30

7. Innate and adaptive immune response	33
7.1 Interferons (IFNs)	33
7.1.1 Induction of interferon	34
7.1.2 Anti-HCV mechanism of interferons	36
7.1.2.1 Anti-HCV mechanisms of type I interferon	36
7.1.2.2 The anti-HCV mechanisms of type II interferon	38
7.1.2.3 Anti-HCV mechanisms of type III interferon	39
7.2 Host-virus interactions in acute hepatitis C	41
7.2.1 Innate immune responses in early acute HCV infection	41
7.2.2 Role of NK cells in the early phase of HCV infection	42
7.2.3 Adaptive immune responses during acute HCV infection	43
7.3 Host-virus interactions in chronic hepatitis C	44
7.3.1 Interferon-stimulated gene expression in chronic hepatitis C	44
7.3.2 Non-response to PegIFN- α in CHC patients with an activated endogenous IFN system in the liver	45
7.3.3 The driving force of ISG expression in CHC	46
7.3.4 NK cell responses in chronic infection	46
7.3.5 Adaptive immune responses in chronic hepatitis C	47
7.3.6 Role of cd3 in HCV infection	50
8. Diagnosis of HCV infection	51
8.1 HCV core antigen assay	51
8.2 Nucleic acid testing for HCV	52
8.3 HCV genotyping	52
8.4 Non-invasive diagnosis of liver fibrosis in chronic hepatitis C	53
8.4.1 Indirect (or class II) markers of liver fibrosis	54
8.4.2 Direct (or class I) markers of liver fibrosis	55
8.5 Imaging techniques	56

Chapter (III): Subjects, Materials and Methods	58
1. Patients and Sample collections	58
2. Protein content determination	59
3. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)	61
4. Immunoblotting Technique (Western Blot)	64
5. Purification of interferon gamma	66
5.1. Preparative gel electrophoresis:	66
5.2. Electroelution	68
6. Detection of gamma interferon using ELISA	70
7. Flow cytometry analysis	73
8. Statistical Analysis	76
Chapter (IV): Results	77
PART (1): The association between IFN-γ level and lymphocyte populations with liver diseases severity	77
1. Demographic data of included patients and normal individuals	77
2. Liver function tests of CHC, HCC patients and healthy individuals	80
3. Detection of INF- γ in HCC and CHC patients	83
3.1. Determination of molecular size of IFN- γ reactive band	85
4. Detection of serum IFN- γ in HCC and CHC patients using ELISA	87
4.1. Dose curve of INF- γ	87
4.2. Standardization of ELISA for detection of INF- γ in CHC and HCC patients	88
4.3. Quantitation of serum IFN- γ in HCC and CHC patients using ELISA	88
4.4. Comparison of levels of INF- γ in sera of CHC patients and HCC	90
4.5. Level of INF- γ in sera of CHC patients according to FIB4 index	91

5. Profile of lymphocyte subsets in peripheral blood in CHC, HCC patients and healthy control	92
5.1. The frequency of lymphocyte subsets in peripheral blood in CHC, HCC patients and healthy control	94
5.2. Analysis of CD3+ T cell and CD4+helper cell and circulating NK cells CD3-/CD16+CD56+ in CHC and HCC patients	95
5.3. Analysis of CD3+ T cell and CD4+helper cell and circulating NK cells CD3-/CD16+CD56+ in fibrosis stages	96
5.4. Analysis of CD3+ T cell and CD4+helper cell and circulating NK cells CD3-/CD16+CD56+ in cirrhotic compensated and decompensated	97
PART (2): IFN-γ level and lymphocyte populations changes in response to combination treatment	98
1. Biochemical response for the 70 treated CHC studied groups after treatment	98
2. Level of IFN- γ for the 70 treated CHC studied groups after treatment	100
3. Profile of lymphocyte subsets in peripheral blood in CHC patients who received the treatment	101
3.1. Profile of lymphocyte subsets in peripheral blood in non-cirrhotic CHC patients treated with daclatasvir and sofosbuvir combination therapy	101
3.2. Profile of lymphocyte subsets in peripheral blood in patients with compensated cirrhosis treated with daclatasvir and sofosbuvir combination therapy	106
3.3. Profile of lymphocyte subsets in peripheral blood in patients with decompensated cirrhosis treated with daclatasvir, sofosbuvir and ribavirin combination therapy	106
Chapter (V): Discussion	111
Chapter (VI): Summary	128
Chapter (VII): References	134
Chapter (VIII): Arabic summary	—

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page</i>
Table 1	Baseline data of CHC, HCC and healthy individuals	79
Table 2	Liver function tests of the studied groups.....	81
Table 3	Relative mobility values of unknown antigen and standard proteins mixture.....	86
Table 4	Dose-response curve of purified 26-kDa INF- γ using ELISA	87
Table 5	Liver function tests for the 70 treated CHC studied groups before and after 3 months treatment	99
Table 6	Mean Percentage of CD3 before and after treatment in non-cirrhotic group.	102
Table 7	Mean Percentage of CD4 before and after treatment in non-cirrhotic group.	103
Table 8	Mean Percentage of CD3-CD16+ before and after treatment in non-cirrhotic group	104
Table 9	Mean Percentage of CD3-CD56+ before and after treatment in non-cirrhotic group	105
Table 10	Mean Percentage of CD3 before and after treatment in compensated and decompensated groups	107
Table 11	Mean Percentage of CD4 before and after treatment in compensated and decompensated groups	108
Table 12	Mean Percentage of CD3-CD16+ before and after treatment in compensated and decompensated groups.....	109
Table 13	Mean Percentage of CD3-CD56+ before and after treatment in compensated and decompensated groups.....	110

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page</i>
Figure a:	Simplified diagram of the structure of the hepatitis C virus	9
Figure b:	Proteins encoded by the HCV genome.....	9
Figure c:	Model of the HCV virus.....	13
Figure 1:	Liver enzymes of CHC., HCC., patients and healthy individuals	82
Figure 2:	Bilirubin (total and direct) of CHC., HCC., patients and healthy individuals.....	82
Figure 3:	Serum Albumin of CHC., HCC., patients and healthy individuals	82
Figure 4:	(A): Detection of INF- γ using Coomassie blue stained SDS-PAGE showing the polypeptide pattern of serum samples from healthy individuals, CHC and HCC patients. (B): Western immunoblot analysis for detection of INF- γ in serum samples from healthy individuals, CHC and HCC patients.....	84
Figure 5:	Linear calibration of log standard molecular weights and their relative mobilities (Rf) for detection of INF- γ	86
Figure 6:	Dose-response curve of purified 26-kDa INF- γ using ELISA	87
Figure 7:	The levels of serum IFN- γ in CHC, HCC patients and healthy controls.....	89
Figure 8:	The levels of serum IFN- γ in CHC and HCC	90
Figure 9:	The levels of serum IFN- γ in CHC patients	91
Figure 10:	Expression of CD3+ T cell and CD4+helper cell and circulating NK cells CD3-/CD16+CD56+.....	93
Figure 11:	Mean percentages of lymphocyte subsets in the healthy, CHC and HCC studied groups	94